June 27, 2007
Insurance companies know the price tag on cancer drugs isn't cheap. Now, a recent study is showing if these drugs are worth their price tag.
Growing concerns from insurance agencies are pushing hospitals to make sure that the health care they are paying money for is affective
"Whether we like it or not, as physicians, we've needed to become more aware of what things cost particularly with our patients who can't pay, when we are trying to figure out a way to get them the drugs they need," said Dr. Heather West, an oncologist at UVA.
Clinical studies funded by the pharmaceutical companies that make Hereceptin and Aromasin have found that in fact the drugs are indeed worth what you pay for them.
The Aromasin study was funded by a grant from Pfizer Inc., which makes the drug.
The Herceptin study was funded partly by Genentech, which makes that drug as well.
"It's been exciting in cancer care to have new medicines come out that really help patients, that really extend lives, that make people feel better," said Dr. James Boyer with Martha Jefferson.